Human trial data is limited to a handful of small pilot studies, and a 2025 University of Utah review concludes BPC-157 should be considered investigational
Structurally, PFAMs consist of a long hydrocarbon chain with an amide group (CONH 2 ) at one end
One daily dose working on plantar fasciitis, Achilles soreness, and peripheral neuropathy simultaneously
Researched effects In a diet-induced-obese mouse study (Neelakantan et al., Biochemical Pharmacology, 2018), subcutaneous 5-Amino-1MQ (20 mg/kg, three times daily, roughly 11 days) produced about 5.1% body-weight loss versus continued weight gain in untreated controls, roughly 35% less epididymal white fat mass, smaller adipocytes, lower plasma cholesterol, and improved glucose tolerance, with no reported change in food intake and no observed adverse effects in the mice
6-alpha-methylprednisolone (1 mg/kg intraperitoneally, once daily) was given alone which produced a considerable worsening and was completely eliminated with coadministration of BPC 157 10 g/kg intraperitoneally
